First AD

Second AD

Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC    

Please briefly discuss the recent data from the CheckMate 214 trial evaluating nivo + ipi for 1L treatment of advanced RCC.

8-year follow-up and subgroup analyses – please comment on OS, DOR, PFS, TFS, and safety (

What insights do the recent HRQoL data provide? (

Please comment on the role of doublet regimens in the 1L setting for advanced RCC and their recent data updates.

Bourlon et al., ASCO GU 2024 Abstract 362)

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma

Peer Exchange

The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes. 

Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER